Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:55 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban
NCT04142658 · Artivion Inc. · PHASE3 · terminated · last registry update 2024-03-20 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Safety” | – | Registry record, Artivion Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against F10 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-03-19Also stopped (terminated): University Health Network, Toronto, Rivaroxaban 10 MG + Placebo (NCT05033314)
- 2025-02-25Results posted on the registry: Thomas L. Ortel, Apixaban 2.5 MG + Placebo (NCT04650087)
- 2025-02-06Results posted on the registry: Atrial Fibrillation Network, Edoxaban + ASA (NCT02618577)
- 2025-02-06Also stopped (terminated): Atrial Fibrillation Network, Edoxaban + ASA (NCT02618577)
- 2025-01-17Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Corticosteroids + Rivaroxaban + Corticosteroids alone (NCT06780462)
- 2024-12-27Also stopped (terminated): National Hospital Organization Osaka National Hospital, Oral Anticoagulant + Antiplatelet Drug (NCT03062319)
- 2024-12-19Phase 3 first posted: National Institute of Cardiovascular Diseases, Pakistan, Apixaban 2.5 MG PO BID + Control (Standard treatment) (NCT06742567)
- 2024-12-13Also stopped (withdrawn): Spark Therapeutics, Inc., SPK-8011 (NCT06297486)
- 2024-12-09Results posted on the registry: Bayer, Asundexian (BAY2433334) + Apixaban (NCT05643573)
- 2024-12-09Also stopped (terminated): Bayer, Asundexian (BAY2433334) + Apixaban (NCT05643573)
- 2024-11-26Results posted on the registry: Washington University School of Medicine, Transdermal patch + Daily Sublingual Tablet (NCT05010707)
- 2024-11-14Results posted on the registry: Palak Shah, Apixaban + Warfarin (NCT04865978)
- 2024-10-29Results posted on the registry: Bristol-Myers Squibb, Apixaban + Standard of Care (NCT02464969)
- 2024-10-08Results posted on the registry: Suleyman Demirel University, Oral Anticoagulant (NCT01924065)
- 2024-09-24Phase 3 first posted: Prof. Stavros Konstantinides, MD, Prevention of Venous Thromboembolism + Placebo Oral Tablet (NCT06611319)
- 2024-08-30Phase 3 first posted: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Aspirin 100mg + Rivaroxaban 10mg (NCT06580223)
- 2024-08-20Results posted on the registry: Institute for Clinical and Experimental Medicine, Apixaban (NCT04974684)
- 2024-08-13Phase 3 first posted: Kafrelsheikh University, Dabigatran Etexilate 150mg + Rivaroxaban 20 MG Oral Tablet (NCT06551402)
- 2024-08-13Phase 3 first posted: Kafrelsheikh University, Dabigatran Etexilate 150mg + Apixaban 5MG (NCT06551415)
- 2024-08-02Results posted on the registry: China National Center for Cardiovascular Diseases, Rivaroxaban (NCT04970381)
- 2024-07-31Phase 3 first posted: Kafrelsheikh University, Apixaban 5MG + Rivaroxaban 20 MG Oral Tablet (NCT06531122)
- 2024-07-26Also stopped (terminated): Hopital Lariboisière, Apixaban 5 mg (NCT03136510)
- 2024-07-19Results posted on the registry: Sangamo Therapeutics, SB-FIX (NCT02695160)
- 2024-07-19Also stopped (terminated): Sangamo Therapeutics, SB-FIX (NCT02695160)
- 2024-07-05Results posted on the registry: Ottawa Hospital Research Institute, Rivaroxaban 10 MG (NCT03506815)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision